USANA Health Sciences (USNA) reported quarterly earnings of $0.74 per share, surpassing the Zacks Consensus Estimate of $0.54 per share. This is an improvement from the $0.54 per share earned during the same period last year. The numbers have been adjusted for one-time events.
This quarterly report indicates an earnings surprise of +37.04%. One quarter prior, it was anticipated that this nutritional supplement company would report earnings of $0.7 per share, but it ended up earning $0.73, resulting in a surprise of +4.29%.
In the past four quarters, the company has exceeded expected earnings per share figures on four occasions.
Tolong support kita ya,
Cukup klik ini aja: https://indonesiacrowd.com/support-bonus/
USANA Health, part of the Zacks Medical – Drugs sector, reported revenue of $235.85 million for the quarter ending June 2025, exceeding the Zacks Consensus Forecast by 4.73%. This is an increase from the $212.87 million in revenue recorded during the same period last year. The company has exceeded revenue expectations according to consensus forecasts on three occasions within the past four quarters.
The long-term viability of the stock’s short-term price changes, influenced by the latest figures and projected future earnings, will largely rely on what the management says during the earnings call.
USANA Health Sciences stock has declined approximately 15.6% from the start of the year, while the S&P 500 has increased by 7.2%.
What Comes Next for USANA Health?
Although USANA Health has performed below the market this year, investors are wondering what lies ahead for the stock.
There are no simple solutions to this important question, but one consistent indicator that can assist investors in dealing with it is the company’s earnings forecast. This not only involves current collective expectations for the upcoming quarter(s), but also how these projections have evolved recently.
Studies indicate a clear link between short-term stock changes and shifts in earnings forecasts. Traders can monitor these changes on their own or use a reliable rating system such as the Zacks Rank, which has a proven history of utilizing the impact of earnings forecast adjustments.
Prior to this earnings announcement, the trend in estimate revisions for USANA Health was varied. Although the size and direction of these revisions may shift after the company’s recently released earnings report, the current situation results in a Zacks Rank #3 (Hold) for the stock. Therefore, the shares are anticipated to perform similarly to the market in the near term. You can view the full list of today’s Zacks #1 Rank (Strong Buy) stocks here.
It will be intriguing to observe how projections for the upcoming quarters and the ongoing fiscal year evolve in the coming days. The current average EPS estimate stands at $0.65 with $225.82 million in revenues expected for the next quarter, and $2.61 with $946.98 million in revenues anticipated for the current fiscal year.
Investors need to be aware that the future prospects of the industry can significantly affect the stock’s performance. Regarding the Zacks Industry Rank, Medical – Drugs is positioned within the top 35% among the over 250 Zacks industries. According to our research, the top 50% of Zacks-ranked industries tend to outperform the bottom 50% by a margin of more than 2 to 1.
A different company in the same sector, Aquestive Therapeutics (AQST), has not yet released its quarterly results for the period ending June 2025.
This specialized pharmaceutical firm is projected to report a quarterly loss of $0.18 per share in its next release, reflecting a year-over-year decrease of -500%. The average EPS forecast for the quarter has stayed the same during the past 30 days.
Aquestive Therapeutics’ revenues are projected to amount to $11.07 million, representing a 44.9% decrease compared to the same quarter in the previous year.
This piece was first published on Zacks Investment Research ().
